Skip to main content
OpenTrials
Completed

NCT Number: NCT07618351

A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients .

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug, Vitalangio1, in healthy male and female volunteers aged 18 to 55 years old.

The main questions it aims to answer are:

What is the safety and tolerability profile of Vitalangio1 following single and multiple-dose administrations? What are the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of Vitalangio1, and how does food intake affect its absorption and drug metabolism? Researchers will compare participants receiving Vitalangio1 tablets with those receiving a placebo to see if the drug is safe, well-tolerated, and demonstrates the expected pharmacological effects compared to no active treatment.

Participants will:

Receive either Vitalangio1 tablets or a placebo orally (through single or multiple escalating doses).

Participate in a 2-period crossover food effect study, taking the study drug under different dietary conditions (fasted vs. fed).

Undergo continuous medical monitoring, including physical examinations, vital sign measurements, ECGs, and provide blood/urine samples to track the drug's metabolic and safety profile.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thrombosis Cardiovascular Diseases Embolism and Thrombosis Vascular Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects aged 18-55 years (including boundary values)
  • Body mass index (BMI) 19-26 kg/m2 (including boundary value), male body weight >= 50.0 kg and <90.0 kg, female body weight >= 45.0 kg and <90.0 kg
  • In good health with no clinically significant abnormalities as determined by physical examination, clinical laboratory tests ,12-lead ECG ,abdominal B-ultrasound and chest X-ray examination
  • Subjects with Fertility (including partners) are willing to voluntarily take effective measures for reasonable contraception within 6 months from the beginning of screening to the last administration of trial drugs; Postmenopausal women should have a menopausal period of >= 1 year ; Within 6 months after receiving the investigational drug, male subjects agreed to use acceptable contraceptive measures and promised not to donate sperm; Female participants agree to use acceptable contraceptive measures and ensure that they do not donate eggs within 6 months from the start of screening until receiving the investigational medication
  • Understand the research procedures and methods, willing and able to give written informed consent and comply with the study procedures and restrictions

Exclusion criteria

  • Vital sign examination: body temperature>37.3 ℃, pulse>100 beats/minute, systolic blood pressure >= 140 mmHg or<90 mmHg, diastolic blood pressure >= 90 mmHg or<50 mmHg; The screening period electrocardiogram examination results showed that QTcF>450 ms (male) or 470 ms (female) or conduction block, which was determined by the researcher to be clinically significant
  • Those who have one or more positive testing at screening for hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, treponema pallidum specific antibody
  • Those who have a history of drug abuse ; have a positive urine drug screen result for drugs of abuse at the screening visit
  • Alanine transaminase, AST, creatinine>ULN; Alkaline phosphatase, bilirubin (total bilirubin or direct bilirubin)>1.5 × ULN
  • Those who are suspected of being allergic to the study drug or any ingredient in the study drug
  • Those who have a history of related diseases that lead to abnormal coagulation function in the past
  • Those who have a history of recurrent or chronic infection within one month prior to screening
  • Those who have undergone surgeries within the first 6 months of screening that have been determined by researchers to affect drug absorption, distribution, metabolism, and excretion
  • Those who consume foods within the first 2 weeks of screening that may affect the metabolism of drugs in the body, or those who are considered by researchers to have other diets that affect drug absorption, distribution, metabolism, and excretion
  • Those who have taken any prescription drugs, Over-the-counter drug, health products and Chinese herbal medicines within 2 weeks before screening, or who have taken within 5 half lives of drugs during screening; Plan to take other investigational drugs not included in this study during the trial period
  • Within one month before screening,any dosage form of vaccine needs to be used
  • Those who donate blood or have a total blood loss of >= 200 mL from 1 month prior to screening to administration, or who donate blood or have a total blood loss of >= 400 mL from 3 months prior to screening to administration, or who have received blood transfusions from 8 weeks prior to screening to administration
  • The investigators believe that the subjects are not suitable for other situations in this experime

Treatment and study plan

Placebo Comparator: Single dose group

Drug

In this randomized, double-blind, placebo-controlled arm, eligible healthy participants will be assigned to different consecutive dose-escalation cohorts. Within each cohort, participants will be randomized to receive either a single oral dose of Vitalangio1 tablets or visually identical placebo tablets. The administration will take place under strict fasting conditions (typically following an overnight fast of at least 10 hours) with a standard volume of water. The study follows a sequential dose-escalation design: the first cohort will receive the lowest predefined starting dose. Subsequent cohorts will only receive the next higher dose level after an independent Safety Review Committee (SRC) thoroughly evaluates the safety, tolerability, and preliminary pharmacokinetic (PK) data from the preceding cohort and confirms it is safe to proceed. The primary focus is to monitor for any acute adverse events and determine the maximum tolerated single dose.

Experimental: Food effect group

Drug

This open-label, randomized, two-sequence, two-perio Vitalangio1. Participants will be randomized to receive a single, fixed oral dose of td crossover arm evaluates how food impacts the absorption and pharmacokinetics of he drug under two alternating conditions: strictly fasted (following an overnight fast) or fed (30 minutes after a standardized high-fat, high-calorie breakfast).

Following the Period 1 administration, a 7-day washout period will be implemented to ensure complete drug elimination. In Period 2, participants will cross over to receive the exact same dose under the alternate dietary condition. No placebo is utilized in this arm. During both periods, intensive blood sampling will be conducted to evaluate and compare key pharmacokinetic parameters, specifically the maximum plasma concentration (Cmax) and area under the curve (AUC), between the fasted and fed states.

Active Comparator: Multiple dose group

Drug

This arm also employs a randomized, double-blind, placebo-controlled, sequential dose-escalation design, but focuses on the cumulative effects of the drug. Healthy participants within each dose cohort will be randomized to receive repeated oral administrations of either Vitalangio1 tablets or a matching placebo. The intervention involves taking the study drug continuously over a predetermined number of consecutive days at a specific frequency (e.g., once or twice daily, as guided by the pharmacokinetic results from the single-dose arm). Administration will typically occur at the same time each day to maintain steady-state drug levels. Similar to the single-dose arm, dose escalation to the next cohort is strictly contingent upon a comprehensive safety and tolerability review of the current cohort's data. This arm is designed to assess steady-state pharmacokinetics, drug accumulation, and sustained safety profiles over a prolonged dosing period.

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From the time of the first dose of the study drug until the end of the final safety follow-up visit (typically up to 7 to 14 days following the last dose administration).

    Safety and tolerability will be evaluated by monitoring the incidence, severity, and causality of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). The assessment also includes monitoring clinically significant changes from baseline in vital signs (such as blood pressure, heart rate, and temperature), 12-lead electrocardiograms (ECGs), physical examinations, and clinical laboratory parameters (hematology, serum chemistry, and urinalysis) across the single-dose, multiple-dose, and food effect groups.

  2. Pharmacokinetics (PK): Maximum Observed Plasma Concentration

    Time frame: Pre-dose and at multiple time points post-dose up to 72 hours (e.g., 0.5, 1, 2, 4, 6, 8, 12, 24, 48, and 72 hours).

    The maximum observed plasma concentration of the active components (e.g., serine protease/nattokinase and relevant metabolites) will be determined from the plasma concentration-time profile.

  3. Number of Participants with Clinically Significant Changes in Clinical Laboratory Parameters

    Time frame: From baseline (Day 0) to Day 14 post-administration.

    Safety assessment includes monitoring the number of participants with clinically significant abnormalities compared to baseline in hematology, serum chemistry, and urinalysis (including liver and kidney function tests).

  4. Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve

    Time frame: Pre-dose and at multiple time points post-dose up to 72 hours.

    The area under the plasma concentration-time curve from time zero to the last measurable concentration will be calculated to assess the total systemic exposure of the intervention.

Secondary outcomes

  1. Change from Baseline in Coagulation Function: Coagulation Factor XI (FXI) Activity

    Time frame: Pre-dose (baseline) and at prespecified time points (e.g., 2, 4, 8, 24, and 48 hours post-dose).

    Pharmacodynamic efficacy will be assessed by measuring the percentage change in plasma Coagulation Factor XI (FXI) activity levels from baseline, evaluating the intervention's impact on the intrinsic coagulation pathway.

  2. Change from Baseline in Standard Coagulation Parameters

    Time frame: Pre-dose (baseline) and at prespecified time points (e.g., 2, 4, 8, 24, and 48 hours post-dose).

    The effect of the intervention on overall coagulation status will be evaluated by measuring the absolute change in activated partial thromboplastin time (aPTT) and prothrombin time (PT) in seconds.

  3. Change from Baseline in Platelet Reactivity

    Time frame: Pre-dose (baseline) and at prespecified time points (e.g., 2, 4, 24, and 48 hours post-dose).

    Platelet function and hyperreactivity will be evaluated by measuring the change from baseline in platelet aggregation, specifically monitoring pathways potentially modulated by the intervention (e.g., high-throughput assessment of receptor-mediated platelet activation, including PEAR1-related pathways). Results will be reported as the percentage of maximal platelet aggregation.

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Registry information

Official study title

A Phase I, Randomized, Double-blind, Placebo-controlled, Single, and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Vitalangio1 in Venous Thromboembolism Patients and a Randomized, Open-label, 2-period Crossover Liver Effect Study

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Jun 1, 2026
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.